Abstract
Introduction: Resistance to chemotherapy continues to impede treatment of hormone receptor negative breast cancer patients. Investigation into the etiology of this resistance shows that GPR30 may participate in communicating downstream signals of growth and proliferation that are traditionally signaled through the estrogen and progestin receptors. Knockdown of GPR30 may aid in diminishing these alternative signaling cascades and therefore allow standard chemotherapeutics to not only hinder proliferation but succeed in promoting cell death.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
